Niemann-Pick Disease (NPD) Market Report 2026

Niemann-Pick Disease (NPD) Market Overview

• Niemann-Pick Disease (NPD) market size has reached to $1.07 billion in 2025 • Expected to grow to $1.79 billion in 2030 at a compound annual growth rate (CAGR) of 10.8% • Growth Driver: The Growing Adoption Of Gene Therapy Driving The Market Growth By Addressing Genetic Mutations And Enhancing Treatment Outcomes • Market Trend: Advancements In Combination Therapy For Niemann-Pick Disease Type C Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Niemann-Pick Disease (NPD) Market?

Niemann-pick disease (NPD) is a rare inherited lysosomal storage disorder caused by mutations in the SMPD1 (Types A and B) or NPC1/NPC2 (Type C) genes, leading to excessive lipid accumulation in cells. This buildup causes progressive damage to the brain, liver, spleen, and other organs. Its symptoms vary by type and may include neurodegeneration, hepatosplenomegaly, respiratory complications, and developmental delays. The main types of niemann-pick disease (NPD) are niemann-pick disease type A, niemann-pick disease type B, and niemann-pick disease type C. Niemann-pick disease type A refers to a rare and severe genetic disorder caused by a deficiency of the enzyme acid sphingomyelinase (ASM), leading to the accumulation of sphingomyelin in various organs. It is treated with various treatments that consist of drugs, physical therapy, and others and is administered through different routes of administration, including oral, intravenous, and subcutaneous. The available distribution channels comprise hospital pharmacies, retail pharmacies, and others and are used by various end users such as hospitals, clinics, and home care settings.

What Is The Niemann-Pick Disease (NPD) Market Growth Forecast?

The niemann-pick disease (npd) market size is expected to see rapid growth in the next few years. It will grow to $1.79 billion in 2030 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to increasing rare disease funding, growth in gene therapy research, expanding newborn screening programs, rising healthcare expenditure, supportive regulatory incentives. Major trends in the forecast period include rising focus on early genetic screening, expansion of orphan drug development, increasing patient advocacy and awareness programs, growth in enzyme replacement and substrate reduction therapies, improved multidisciplinary disease management approaches.

Global Niemann-Pick Disease (NPD) Market Segmentation

1) By Type: Niemann-Pick Disease Type A, Niemann-Pick Disease Type B, Niemann-Pick Disease Type C 2) By Treatment Type: Drugs, Physical Therapy, Other Treatment Types 3) By Route Of Administration: Oral, Intravenous, Subcutaneous 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels 5) By End-User: Hospitals, Clinics, Homecare Settings Subsegments: 1) By Niemann-Pick Disease Type A: Infantile-Onset Niemann-Pick Disease, Neurodegenerative Niemann-Pick Disease, Acute Visceral Niemann-Pick Disease, Severe Lysosomal Storage Disorder 2) By Niemann-Pick Disease Type B: Late-Onset Niemann-Pick Disease, Non-Neurological Niemann-Pick Disease, Chronic Visceral Niemann-Pick Disease, Mild Lysosomal Storage Disorder 3) By Niemann-Pick Disease Type C: Early-Onset Niemann-Pick Disease, Juvenile Niemann-Pick Disease, Adult-Onset Niemann-Pick Disease, Progressive Neurodegenerative Niemann-Pick Disease

What Is The Driver Of The Niemann-Pick Disease (NPD) Market?

The growing adoption of gene therapy is expected to propel the growth of the niemann-pick disease (NPD) market going forward. Gene therapy is a medical technique that involves modifying or manipulating a person's genes to treat or prevent disease. Gene therapy is rising due to advances in genetic engineering, enabling precise and effective gene modifications that improve treatment outcomes for genetic disorders. Gene therapy helps in the treatment of niemann-pick disease (NPD) by targeting the underlying genetic mutations, aiming to correct the enzyme deficiencies that cause the disorder and improve cellular function. For instance, in January 2024, according to the American Society of Gene and Cell Therapy, a US-based organization for gene and cell therapy, the number of gene therapies in Phase III trials rose by 10% in the fourth quarter of 2023 compared to the previous quarter, representing the first increase since the third quarter of 2022. Therefore, the growing adoption of gene therapy is driving the growth of the niemann-pick disease (NPD) industry.

Key Players In The Global Niemann-Pick Disease (NPD) Market

Major companies operating in the niemann-pick disease (npd) market are Sanofi S.A., Mayo Clinic, Cincinnati Children's Hospital Medical Center, Boston Children's Hospital, Mallinckrodt Pharmaceuticals plc, Myriad Genetics, CENTOGENE N.V., The Florey Institute of Neuroscience and Mental Health, National Organization for Rare Disorders (NORD), Evox Therapeutics Limited, Bloomsbury Genetic Therapies Ltd., Cyclo Therapeutics Inc., CarelonRx, Rainbow Children's Hospital, Vtesse Inc., Orphazyme A/S, Zebra Biologics, Sarepta Therapeutics Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Ultragenyx Pharmaceutical Inc., Passage Bio, Amicus Therapeutics Inc., PTC Therapeutics, SOM Biotech, ENDECE, StrideBio, Mandos Health, BioMarin Pharmaceutical Inc.

Global Niemann-Pick Disease (NPD) Market Trends and Insights

Major companies operating in the niemann-pick disease (NPD) market are focusing on developing advanced treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. Combination therapy involves the administration of two or more therapeutic agents or treatment strategies to address a disease or medical condition. This method aims to improve effectiveness and minimize resistance to single-agent therapy (monotherapy). For instance, in September 2024, Zevra Therapeutics Inc., a US-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for MIPLYFFA, in combination with miglustat, for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in both adult and pediatric patients aged 2 years and older. MIPLYFFA (arimoclomol) works by enhancing the production of heat shock proteins (HSPs), which aid in clearing toxic lipid buildup and protect neurons from damage. Meanwhile, miglustat inhibits glucosylceramide synthase, thereby reducing lipid accumulation. Together, the two therapies help slow the progression of neurological decline in NPC patients.

What Are Latest Mergers And Acquisitions In The Niemann-Pick Disease (NPD) Market?

In September 2024, Zevra Therapeutics, a US-based biopharmaceutical company, partnered with Orsini to serve as the exclusive specialty pharmacy provider for its newly approved Niemann-Pick disease type C therapy. Through this collaboration, Zevra aims to ensure broad patient access to MIPLYFFA (arimoclomol), the first FDA-approved treatment for Niemann-Pick disease type C (NPC), by leveraging Orsini’s specialty pharmacy network for distribution and patient support. Orsini is a US-based company providing specialty pharmacy services for rare and complex diseases.

Regional Outlook

North America was the largest region in the niemann-pick disease (NPD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Niemann-Pick Disease (NPD) Market?

The niemann-pick disease (NPD) market consists of revenues earned by entities by providing services such as diagnostic testing, genetic counseling, patient support programs, clinical trial management, drug development, and regulatory consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. The niemann-pick disease (NPD) market also includes sales of gene therapy products, enzyme replacement tools, diagnostic kits, biomarker testing tools, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Niemann-Pick Disease (NPD) Market Report 2026?

The niemann-pick disease (npd) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the niemann-pick disease (npd) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.